Hepatitis b drug trial halted early after safety check
NCT ID NCT02797522
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested an experimental drug called ARC-521 in healthy volunteers and people with chronic hepatitis B. The main goal was to check safety and how the body processes the drug. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site 1
Grafton, Auckland, 1011, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple roadside test catch liver disease before it turns deadly?
- Hospital care model aims to treat opioid addiction and serious infections together
- Simple blood test aims to spot multiple cancers early
- Heart safety check for hepatitis b drug candidate
- Two-Drug combo aims to cure chronic hepatitis b
- Hepatitis b breakthrough? study checks if bepirovirsen response lasts